Please ensure Javascript is enabled for purposes of website accessibility

Why Tonix Pharmaceuticals Stock Surged Today

By Joe Tenebruso - Feb 8, 2021 at 8:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech wants to help doctors measure T-cell immunity to the novel coronavirus.

What happened

Shares of Tonix Pharmaceuticals (TNXP 14.93%) jumped 22% on Monday after the biopharmaceutical company said it would develop a COVID-19 skin test. 

So what 

Tonix intends to develop a diagnostic skin test, called TNX-2100, to measure T-cell immunity to SARS-CoV-2, the virus that causes COVID-19. Researchers believe T-cell immunity can help protect against severe forms of the disease.

"We believe TNX-2100 has the potential to measure T-cell immunity to CoV-2 and therefore serve as an aid to COVID-19 diagnosis to support patient care, public health surveillance, and vaccine trials," Tonix CEO Seth Lederman said in a press release.

A person points to an upwardly sloping stock chart.

Tonix Pharmaceuticals' stock price popped on Monday. Image source: Getty Images.

Tonix expects its test to provide time- and cost-savings compared to current T-cell immunity tests that require specialized laboratory equipment. TNX-2100 is also designed to be administered in a wider variety of healthcare settings.

Tonix plans to begin clinical trials of TNX-2100 in the second half of 2021, subject to regulatory clearance.

Now what

Tonix also announced a stock offering on Monday. The biotech will sell approximately 58.3 million shares to investors at a price of $1.20 per share. Tonix expects to raise roughly $70 million, which it can use to fund the development of TNX-2100 and other clinical studies. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tonix Pharmaceuticals Holding Corp. Stock Quote
Tonix Pharmaceuticals Holding Corp.
$2.54 (14.93%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.